Axon Enterprise, Inc. (NASDAQ:AXON) Shares Bought by Quantinno Capital Management LP

Quantinno Capital Management LP increased its holdings in Axon Enterprise, Inc. (NASDAQ:AXON - Free Report) by 11.2% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 8,724 shares of the biotechnology company's stock after acquiring an additional 878 shares during the quarter. Quantinno Capital Management LP's holdings in Axon Enterprise were worth $5,185,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Capital World Investors raised its stake in Axon Enterprise by 86.4% during the 4th quarter. Capital World Investors now owns 1,815,765 shares of the biotechnology company's stock valued at $1,079,145,000 after acquiring an additional 841,772 shares during the last quarter. Alliancebernstein L.P. raised its position in Axon Enterprise by 273.8% during the 4th quarter. Alliancebernstein L.P. now owns 1,109,045 shares of the biotechnology company's stock worth $659,128,000 after buying an additional 812,337 shares during the last quarter. Norges Bank acquired a new stake in shares of Axon Enterprise in the 4th quarter worth $482,081,000. GQG Partners LLC acquired a new position in shares of Axon Enterprise during the fourth quarter worth about $478,349,000. Finally, Vanguard Group Inc. increased its position in Axon Enterprise by 3.4% during the 4th quarter. Vanguard Group Inc. now owns 8,446,437 shares of the biotechnology company's stock worth $5,019,886,000 after purchasing an additional 275,959 shares during the period. 79.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts recently commented on the stock. Barclays raised their price objective on shares of Axon Enterprise from $726.00 to $735.00 and gave the company an "overweight" rating in a research note on Friday, May 9th. Needham & Company LLC increased their price target on Axon Enterprise from $600.00 to $750.00 and gave the stock a "buy" rating in a research note on Thursday, May 8th. JMP Securities reiterated an "outperform" rating on shares of Axon Enterprise in a report on Tuesday, February 4th. Craig Hallum lowered shares of Axon Enterprise from a "buy" rating to a "cautious" rating in a report on Monday, March 10th. Finally, Northcoast Research downgraded Axon Enterprise from a "buy" rating to a "neutral" rating in a report on Wednesday, February 19th. One analyst has rated the stock with a sell rating, one has issued a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $652.73.

Axon Enterprise Stock Performance

AXON stock traded up $0.43 during trading on Tuesday, hitting $742.75. 383,468 shares of the company's stock traded hands, compared to its average volume of 751,632. The stock has a market capitalization of $57.82 billion, a price-to-earnings ratio of 191.93, a price-to-earnings-growth ratio of 5.17 and a beta of 1.24. Axon Enterprise, Inc. has a 52 week low of $273.52 and a 52 week high of $744.51. The stock has a fifty day moving average price of $592.46 and a two-hundred day moving average price of $598.92. The company has a quick ratio of 2.63, a current ratio of 2.96 and a debt-to-equity ratio of 0.32.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last issued its earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.34 by $0.07. The firm had revenue of $603.63 million for the quarter, compared to analysts' expectations of $585.67 million. Axon Enterprise had a net margin of 15.37% and a return on equity of 7.50%. Axon Enterprise's revenue was up 31.3% on a year-over-year basis. During the same quarter last year, the company posted $1.15 earnings per share. As a group, equities analysts anticipate that Axon Enterprise, Inc. will post 5.8 EPS for the current fiscal year.

Insider Buying and Selling at Axon Enterprise

In other news, Director Matthew R. Mcbrady sold 400 shares of the business's stock in a transaction on Wednesday, May 14th. The stock was sold at an average price of $718.40, for a total value of $287,360.00. Following the sale, the director now owns 3,492 shares of the company's stock, valued at approximately $2,508,652.80. The trade was a 10.28% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Caitlin Elizabeth Kalinowski sold 1,300 shares of the firm's stock in a transaction dated Monday, May 19th. The shares were sold at an average price of $738.84, for a total value of $960,492.00. Following the transaction, the director now directly owns 4,829 shares of the company's stock, valued at $3,567,858.36. This represents a 21.21% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 25,064 shares of company stock worth $15,817,127. 4.40% of the stock is owned by insiders.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.